Clinical trials: sponsored by Intra-Cellular Therapies, Inc.
Heart Failure, Systolic
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
- Trial name
- NCT03387215
- Testing
- ITI-214
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
This is a single site, randomized, double-blind, placebo-controlled, within-subjects study design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using functional magnetic resonance imaging (fMRI) to…
- Trial name
- NCT03489772
- Testing
- ITI-214
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics…
- Trial name
- NCT03257046
- Testing
- ITI-214
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Alzheimer's Disease
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients with Dementia
- Trial name
- NCT02078310
- Testing
- ITI-007
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.
- Trial name
- NCT02288845
- Testing
- ITI-007
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda